Hammond E H, Watson F S, Bristow M R, O'Connell J B, Gilbert E M, Doty D B, Renlund D G
Department of Internal Medicine, University of Utah Medical Center, Salt Lake City 84132.
J Heart Transplant. 1990 May-Jun;9(3 Pt 1):236-8.
The murine monoclonal CD3 antibody (OKT3) is effective in the treatment of refractory renal and cardiac allograft rejection and holds promise for improving rejection prophylaxis in heart transplantation. Although the administration of OKT3 is associated with many side effects, arteritis has not been previously reported. We report the development of acute necrotizing temporal arteritis associated with the deposition of mouse immunoglobulin G in a heart transplant recipient receiving OKT3 treatment of refractory rejection.
鼠单克隆CD3抗体(OKT3)在治疗难治性肾和心脏移植排斥反应方面有效,有望改善心脏移植中的排斥反应预防。尽管使用OKT3会伴随许多副作用,但此前尚未有动脉炎的报道。我们报告了一名接受OKT3治疗难治性排斥反应的心脏移植受者发生急性坏死性颞动脉炎,并伴有小鼠免疫球蛋白G沉积。